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Abstract
Epidemiological studies have shown that short or insufficient sleep is associated with increased risk for metabolic diseases
and mortality. To elucidate mechanisms behind this connection, we aimed to identify genes and pathways affected by
experimentally induced, partial sleep restriction and to verify their connection to insufficient sleep at population level. The
experimental design simulated sleep restriction during a working week: sleep of healthy men (N= 9) was restricted to 4 h/
night for five nights. The control subjects (N = 4) spent 8 h/night in bed. Leukocyte RNA expression was analyzed at
baseline, after sleep restriction, and after recovery using whole genome microarrays complemented with pathway and
transcription factor analysis. Expression levels of the ten most up-regulated and ten most down-regulated transcripts were
correlated with subjective assessment of insufficient sleep in a population cohort (N = 472). Experimental sleep restriction
altered the expression of 117 genes. Eight of the 25 most up-regulated transcripts were related to immune function.
Accordingly, fifteen of the 25 most up-regulated Gene Ontology pathways were also related to immune function, including
those for B cell activation, interleukin 8 production, and NF-kB signaling (P,0.005). Of the ten most up-regulated genes,
expression of STX16 correlated negatively with self-reported insufficient sleep in a population sample, while three other
genes showed tendency for positive correlation. Of the ten most down-regulated genes, TBX21 and LGR6 correlated
negatively and TGFBR3 positively with insufficient sleep. Partial sleep restriction affects the regulation of signaling pathways
related to the immune system. Some of these changes appear to be long-lasting and may at least partly explain how
prolonged sleep restriction can contribute to inflammation-associated pathological states, such as cardiometabolic diseases.
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Introduction
In addition to compromised brain function, restriction of sleep
has many adverse effects on human physiology and health.
Epidemiologic studies have shown an association between self-
reported sleep duration and cardiometabolic diseases: sleep
duration that deviates from 7–8 h per night is associated with
several cardiovascular risk factors, including elevated blood
pressure, increased heart rate [1], coronary heart disease [2,3],
obesity [4], and type II diabetes [5,6]. Both overall mortality and
mortality of cardiovascular diseases are increased in individuals
who sleep less than 7 hours [7–10].
Experimental sleep restriction (SR) studies have provided data
that give some insight into the potential mechanism that may
explain the increase in cardiometabolic diseases. Increased blood
pressure and heart rate during and after sleep restriction has been
a frequent finding in studies where sleep has been totally or
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partially restricted [3,11,12]. Possible metabolic consequences of
sleep restriction include the development of insulin resistance, a
state that precedes type II diabetes [13], increase of serum ghrelin
levels and decrease [13,14] or increase [15] of leptin levels. These
changes may contribute to the increased food intake during SR
and predispose to development of obesity [13].
Experimental sleep restriction studies conducted in humans and
using animal models consistently show activation of immune
defense during sleep restriction. Increased levels of pro-inflamma-
tory cytokines [16–18] and C-reactive protein (CRP) [19,20] as
well as activation of nuclear factor kappa B (NF-kB) [21,22] have
been reported. Prolonged low level activation of these inflamma-
tory markers is also associated with several chronic diseases,
including cardiovascular diseases and type II diabetes [23]. Thus
there is compelling evidence on the connection between SR,
activation of immune function-related molecular pathways and
cardiometabolic diseases.
We have previously reported that partial SR increased serum
levels of CRP, changed the numbers of blood leukocytes, and
activated the peripheral blood mononuclear cells [19]. The
activation was evidenced as increased gene expression and protein
levels of selected cytokines, interleukins (ILs) 1b, 6, and 17, as
response to in vitro immunological challenge. These extensive
changes in the immune responses prompted us to further
characterization of the patterns using genome-wide gene expres-
sion analysis.
One important question that has remained largely unexplored
concerns the relationship between findings produced in short-term
experimental studies and the real life exposure to sleep restriction,
which mostly can be characterized as partial and long-term. The
epidemiologic data is based on the latter condition, and it is
important to build bridges between the experimentally created
data and the data collected in epidemiologic research from real life
conditions.
In the present study we used two strategies to decrease this gap:
1) the experimental part of the study was planned to mimic real life
conditions, and 2) we collected biological data, including gene
expression data, from an epidemiologic cohort. We believe that
combining these data sets will increase our understanding also on
the relationships between experimental and real life conditions.
In the experimental part, sleep of healthy volunteers was
restricted to 4 hours per day during five days, followed by two
nights of recovery sleep. We have earlier reported changes in
glucose metabolism [15], and cytokines, white blood cell
subpopulations, and C-reactive protein [19] from this experiment).
Gene expression was assessed using whole genome microarrays at
baseline, after the SR period, and after recovery. These conditions
were compared within the subjects as well as with the control
group who spent the same time in the laboratory but spent eight
hours per night in bed. In the population study, the most
significantly affected genes, identified in the experimental study,
were correlated with self-reported insufficient sleep as an indicator
of sleep restriction in a Finnish population cohort of 472
individuals.
To the best of our knowledge, this is the first study to address
changes in gene expression at whole genomic level in response to
partial, cumulative sleep loss in humans, and insufficient sleep at
population level.
Results
Changes in gene expression in the experimental SR study were
assessed in peripheral blood mononuclear cells (PBMC) with
genome-wide microarrays. The microarray data were analyzed at
two levels: at single gene level and at gene network level.
The single gene analysis consisted of identifying transcripts that
were differently expressed after SR. We chose to perform a
conservative, stepwise analysis aiming to retain transcripts with
significant effect but modest P value in the analysis.
The network analysis aimed to find biological gene networks
that were significantly changed after SR.
Analysis of the single transcripts
The final probe filtering and data analysis was performed
stepwise in three phases (see Figure 1).
Phase 1 (Figure 1a). The expression levels of altogether 2331
transcripts (1292 up-regulated and 1039 down-regulated) were
changed with at least 1.2-fold after 5 nights of partial SR
compared to BL (Figure 1a).
Phase 2 (Figure 1b). 2-way ANOVA. In order to evaluate the
statistical significance of the differentially expressed genes, in the
first phase 2-way repeated measures ANOVA was adopted (R/
Bioconductor open software packages; http://www.r-project.org)
covering the three timepoints (BL, SR, REC) and the case/control
group, as well as their interaction. A conservative cut-off of
P,0.05 (for the interaction) was used to filter out most of the
transcripts, leaving 310 for further analyses. Of these, 227 were
up-regulated and 83 down-regulated. The fold change differences
are presented in Figure 2 and the genes are listed in Tables S1
and S2.
Phase 3 (Figure 1c). 1-way ANOVA and t tests. To eliminate
the changes occurring also in the control subjects, the analysis
from phase 2 was continued with 1-way repeated measures
ANOVA of the timepoint axis, analyzing the experimental group
and the control group separately. The individual timepoints were
compared using paired t tests, comparing the SR and REC
Figure 1. Analysis strategy. The flow of statistical analysis and the
amount of entities (genes/transcripts) after each step are illustrated. a)
The 15101 entities that passed the filtering by flags and reannotation
included 1292 up-regulated (red) and 1039 down-regulated (green)
transcripts with at least 1.2-fold change from baseline (BL) to sleep
restriction (SR) in sleep-restricted subjects ( = cases). * The pathway
analysis was run for these genes. b) The 2331 entities were analyzed
with 2-way ANOVA using the case/control status and the three
timepoints as analysis axes. Changes with ANOVA interaction P value
,0.05 were observed in 227 up-regulated and 83 down-regulated
transcripts. c) Altogether 310 entities were further analyzed with 1-way
repeated measures ANOVA considering the three timepoints. The 43
entities showing changes also in the control group were excluded from
the analysis. The 133 genes with 1-way ANOVA P value ,0.05 for the
cases but not for the controls were then analyzed using a t test
between the timepoints BL and SR. 62 genes were up-regulated and 55
down-regulated (P,0.05).
doi:10.1371/journal.pone.0077184.g001
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timepoints to BL. Between BL and SR, the expression of 117
transcripts was changed in the experimental group, but not in the
control group. 62 transcripts were up-regulated and 55 down-
regulated. The top 25 up- and down-regulated transcripts are
listed in order of fold change from BL to SR in Tables 1 and 2,
respectively. Most of the expression changes returned back to BL
levels during two nights of 6 recovery, but 14 genes remained up-
regulated and 6 down-regulated in REC (paired t test, pointwise
P,0.05).
Of the top 25 most up-regulated transcripts, at least 8 (TLR4,
IKZF1, FPR2, FCRL2, CYBB, SOCS3, SWAP70, DLG1) have been
annotated to immune-related GO pathways. There were also
several stress and/or apoptosis-related transcripts (HIPK3, BTG2,
SRFBP1) among the most up-regulated transcripts.
Of the top 25 most down-regulated genes, 19 were immune-
related, mostly related to natural killer cell (NK cell) function (such
as KIR3DL1, NCAM1, GZMB, GZMH, KLRF1, NKG7, KLRB1,
DDX20, GNLY). As the number of NK cells was reduced during
SR, the reduction in the expression level of these genes could be a
consequence of this reduction.
The expression levels of six of the genes related to immune
functions or stress/apoptosis (BTG2, FCRL2, HIPK3, IKZF1,
STX16, and TGFBR3) were validated with quantitative PCR
(qPCR) analysis. Four of these (BTG2, FCRL2, IKZF1, and STX16)
were up-regulated and one (TGFBR3) down-regulated after SR
(P,0.05), confirming the results obtained with the microarray
analysis (Table S3).
Figure 2. Expression changes after partial sleep restriction. The
310 entities (genes/transcripts) with interaction P value (P,0.05) in 2-
way ANOVA, sorted by average fold change from baseline (BL) to sleep
restriction (SR) (with the up-regulated (red) on top, followed by the
down-regulated (green). Each lane represents one individual (sleep
deprived subjects, N = 9; controls, N = 4), and colour codes represent the
fold change from BL to SR (BL = 1).
doi:10.1371/journal.pone.0077184.g002
Table 1. Up-regulated genes after cumulative sleep
restriction.
SR to BL
Affymetrix Probe Gene symbol P value Fold change
221060_s_at TLR4 0.0218 1.91
210148_at HIPK3 0.0016 1.91
214590_s_at UBE2D1 0.0047 1.71
216901_s_at IKZF1 0.0031 1.71
201235_s_at BTG2 0.0029 1.65
210773_s_at FPR2 0.0069 1.63
221638_s_at STX16 0.0030 1.63
221239_s_at FCRL2 0.0033 1.58
203923_s_at CYBB 0.0227 1.53
215159_s_at NADK 0.0056 1.50
202874_s_at ATP6V1C1 0.0008 1.46
227697_at SOCS3 0.0016 1.46
224917_at MIRN21 0.0149 1.45
1552787_at HELB 0.0030 1.44
224760_at SP1 0.0015 1.43
210772_at FPR2 0.0074 1.39
201669_s_at MARCKS 0.0248 1.38
241734_at SRFBP1 0.0029 1.37
210872_x_at GAS7 0.0123 1.34
209306_s_at SWAP70 0.0003 1.34
208650_s_at CD24 0.0027 1.33
217208_s_at DLG1 0.0235 1.33
206359_at SOCS3 0.0043 1.32
201971_s_at ATP6V1A 0.0029 1.32
231955_s_at HIBADH 0.0369 1.31
The expression changes of the 25 most up-regulated genes/transcripts after
experimental sleep restriction period (SR) compared to baseline values (BL).
Pointwise P values and fold changes (SR expression/BL expression) between
these two timepoints are shown for each transcript.
doi:10.1371/journal.pone.0077184.t001
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Transcription factor binding site analysis
Enrichment of binding sites for specific transcription factors
among the up- or down-regulated genes was analyzed using the
over-representation analysis tool oPOSSUM. Human single site
analysis was applied as described in [24].
Binding sequences for eight vertebrate transcription factors
(Prrx2, IRF2, Nobox, NFYA, STAT1, Pdx1, SRY, and Pax5)
were significantly over-represented in the up-regulated transcripts
(one-tailed Fisher exact probability test P,0.05). Of the genes
coding for these transcription factors, interferon regulatory factor
2 (IRF2; pointwise P=0.020, and fold change (FC) = 1.50) and
signal transducer and activator of transcription 1 (STAT1;
pointwise P=0.027, FC=1.38) showed higher expression after
SR (compared to BL with t test) in the microarray analysis.
Among the down-regulated transcripts, binding sequences for
five transcription factors (PBX1, Fos, RELA, GABPA, MYC-
MAX, and Nobox) were enriched (P,0.05). None of the mRNAs
coding for these were decreased after SR in the microarray
analysis (Fos expression was up-regulated; pointwise P=0.015,
FC=2.80).
Analysis of biological networks
In order to characterize which biological pathways were
enriched, a nonparametric in house developed CIGA pathway
analysis program was used. This program uses Gene Ontology
(GO) annotations that group the single genes in biologically
meaningful pathways [25]. The GO pathways were assessed
among all transcripts that had passed the quality control (N= 15
101).
Up-regulated pathways included highly significant enrichment of
inflammation and immunity related GOs (P,0.001, P,0.05 after
permutation) (Tables 3 and S4). Two major functional groups
were identified: the activation of leukocytes and adaptive
immunity, and the activation of cytokine pathways. The most
significant pathways were B cell activation and interleukin 8
production (P,1025, P,0.001 after permutation; the following P
values given are those obtained after permutation).
As a feature of the tree-like structure of the GO classifications,
many of the pathways overlap. Of the 25 most significant
pathways, genes comprising eight pathways related to leukocyte
activation and adaptive immune response (B cell activation,
leukocyte activation, cell activation, lymphocyte activation,
adaptive immune response, adaptive immune response based on
somatic recombination of immune receptors built from immuno-
globulin superfamily domains, leukocyte differentiation, and
lymphocyte differentiation) overlapped considerably (Table 3).
The ten most frequent genes from these lymphocyte activation-
related pathways (8 pathways altogether) were: CD24L4, COPEB
(KLF6), CTLA4, AC, MS4A1, LIG4, CD86, SKAP2, HLX, and
BCL6.
In the activation of cytokine pathways group the overlapping
genes comprised of six pathways (IL-8 biosynthesis, positive
regulation of IL-8 biosynthesis, IL-8 production, lipopolysaccha-
ride binding (all P,0.001), and positive regulation of cytokine
biosynthesis (P,0.005)). The ten most frequent transcripts from
the cytokine biosynthesis pathways (altogether 6 pathways) were:
TLR4, TLR8, BCL10, BPI, PTAFR, CD86, TLR2, MYD88, SYK,
and TLR1.
Also xenobiotic process (P,0.001) and response to xenobiotic
stimulus (P,0.005), I-kB kinase–NF-kB cascade (P,0.005), and T
helper 2 cell differentiation (P,0.01) were among the significantly
enriched pathways.
In addition to the immunological pathways, we observed
significant enrichment of GOs related to blood coagulation
(P,0.001), oxygen transport (oxygen transport, gas transport
(P,0.001)), and hemoglobin catabolism (hemoglobin complex
(P,0.001), heme catabolic process (P,0.001), pigment catabolic
process (P,0.005)). Also phospholipid binding (P,0.005) and
Arp2/3 complex (P,0.001) were enriched among the up-
regulated transcripts.
Down-regulated pathways included an enrichment of a biologically
different set of GOs, listed in Table S5. These included pathways
participating in lipid transport; intracellular lipid transport,
cholesterol efflux, sequestering of lipid, and sterol transporter
activity (P,0.001) being the top-ranked. Altogether more than half
of the first 25 top-ranked pathways were related to lipid
metabolism or transport. Only one directly immune-related
pathway was among this group: the MHC class I receptor activity
pathway.
Interferon c in stimulated leukocytes
Stimulation of PBMC with phytohaemagglutinin (PHA)
resulted in lower level of interferon-c (IFN-c) protein in samples
taken after SR (mean 6 SD 5.3462.39 mg/l) compared to the
Table 2. Down-regulated genes after experimental sleep
restriction.
SR to BL
Affymetrix
Probe Gene symbol P value Fold change
211687_x_at KIR3DL1 0.0036 0.46
210164_at GZMB 0.0017 0.54
212843_at NCAM1 0.0004 0.57
228774_at CEP78 0.0020 0.59
210321_at GZMH 0.0019 0.59
220646_s_at KLRF1 0.0055 0.60
227819_at LGR6 0.0041 0.60
228063_s_at NAP1L5 0.0050 0.61
37145_at GNLY 0.0015 0.61
205495_s_at GNLY 0.0019 0.62
207072_at IL18RAP 0.0060 0.63
226625_at TGFBR3 0.0040 0.64
226858_at CSNK1E 0.0179 0.65
210140_at CST7 0.0029 0.65
220684_at TBX21 0.0022 0.66
213915_at NKG7 0.0048 0.66
206267_s_at MATK 0.0011 0.67
202146_at IFRD1 0.0206 0.68
205291_at IL2RB 0.0093 0.68
209993_at ABCB1 0.0048 0.69
1553736_at CCDC131 0.0009 0.70
214450_at CTSW 0.0041 0.70
235232_at GMEB1 0.0040 0.71
214470_at KLRB1 0.0046 0.72
224315_at DDX20 0.0318 0.72
The expression changes of the 25 most down-regulated genes/transcripts after
experimental sleep restriction period (SR) compared to baseline values (BL).
Pointwise P values and fold changes (SR expression / BL expression) between
these two timepoints are shown for each transcript.
doi:10.1371/journal.pone.0077184.t002
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cells stimulated after BL conditions (4.4162.27 mg/ml)
(P=0.049).
RNA expression in the population sample
The National FINRISK Study is a cross-sectional study
performed every fifth year since 1972. Its aim is to evaluate the
cardiovascular risk factors in Finland using questionnaires,
laboratory measurements, and information on general health of
the participants [26]. Lifestyle and Genetic determinants of
Obesity and Metabolic Syndrome (DILGOM) study was per-
formed as an extension of the FINRISK 2007 study comprising
also whole genome RNA expression data from altogether 518
individuals (age 25–74 years). One question in the question-
naire was particularly aimed at estimating the grade of sleep debt:
‘‘Do you, in your opinion, sleep enough?’’ with answering options: 1)
‘‘Yes, almost always’’ (N= 168), 2) ‘‘Yes, often’’ (N= 218), 3) ‘‘Seldom or
almost never’’ (N= 86), and 4) ‘‘I cannot say’’ (N= 46). Answer 4
was excluded, and answers 1–3 (N= 472) were dichotomized
Table 3. Gene Ontology pathways up-regulated after sleep restriction.
Pathway P value
Total
genes
Gene
rank
Top
genes Contributing genes
B cell activation 0.001 90 1868 43 AC, COPEB, LIG4, CD24L4, SKAP2, MS4A1,
BCL6, MS4A1, MS4A1, CD79A
interleukin-8 production 0.001 9 1282 8 BPI, TLR4, TLR8, BCL10, TLR7
lipopolysaccharide binding 0.001 9 1282 8 TLR2, PTAFR, BPI, TLR4, PTAFR
xenobiotic metabolic process 0.001 8 352 5 DEFA4, KYNU, S100A12
coagulation 0.001 75 821 22 C3AR1, NELL2, PLSCR1, ANXA5, ENTPD1, NID1,
PTAFR, PLXDC2, RAB27A, CD36
leukocyte activation 0.001 208 1499 68 AC, COPEB, CTLA4, HLX, LIG4, CD24L4, SKAP2,
MS4A1, BCL6, CD86
cell activation 0.002 217 1499 70 AC, COPEB, CTLA4, PLSCR1, HLX, LIG4, CD24L4,
SKAP2, MS4A1, BCL6
adaptive immune resp. based on
somatic recomb. of immune receptors built
from IG
superfamily domains
0.002 83 2853 51 AC, HLX, LIG4, CD24L4, BCL6, CD86, RAB27A,
CR1, MYD88, LY9
phospholipid binding 0.003 91 1083 29 DGKA,ANXA5, OSBPL1A, SNX3, PTAFR, DGKA,
SGK1, DAPP, ANXA2, EPB41
lymphocyte activation 0.002 184 1499 61 AC, COPEB, CTLA4, HLX, LIG4, CD24L4, SKAP2,
MS4A1, BCL6, CD86
positive regulation of interleukin-8
biosynthetic process
0.001 8 1282 7 TLR4, TLR8, BCL10, TLR7
interleukin-8 biosynthetic process 0.001 8 1282 7 TLR4, TLR8, BCL10, TLR7
regulation of interleukin-8
biosynthetic process
0.001 8 1282 7 TLR4, TLR8, BCL10, TLR7
oxygen transport 0.001 10 1329 8 HBG1, HBA2
hemoglobin complex 0.001 10 1329 8 HBG1, HBA2
adaptive immune response 0.001 88 2853 53 AC, HLX, LIG4, CD24L4, BCL6, CD86, IL6ST,
RAB27A, CR1, MYD88
leukocyte differentiation 0.002 110 2624 60 COPEB, CTLA4, HLX LIG4, CD24L4, BCL6, CD86,
CD79A, CTLA4
response to xenobiotic stimulus 0.003 10 352 5 DEFA4, KYNU, DEFA1, S100A12
Arp2/3 protein complex 0.001 15 3855 15 ACTR2, ACTR3, ARPC5, ARPC1B, TTLL3
lymphocyte differentiation 0.005 93 1482 35 COPEB, CTLA4, HLX LIG4, CD24L4, BCL6, CD86,
CD79A, CTLA4, ZEB1
I-kappaB kinase/NF-kappaB cascade 0.003 107 1499 39 AZI2, TLR2, UBE2N, LY96, CFLAR, TIFA, RP11-
119B16.1, MYD88, CASP1, CD40
positive regulation of cytokine
biosynthetic process
0.003 26 2593 19 CD86, MYD88, SYK, TLR1, TLR4, TLR8, BCL10,
TLR7, STAT5B, CD86
gas transport 0.001 11 1329 8 HBG1, HBA2, RP3-402L9.2,CA2
blood coagulation 0.006 65 588 15 C3AR1, NELL2, PLSCR1, ANXA5, ENTPD1, NID1,
PTAFR, PLXDC2, RAB27A, CD36
response to fungus 0.001 17 1282 10 DEFA4, TLR2, DEFA1, S100A12, MYD88, TLR4,
BCL10, CLEC7A, COTL1, PTX3
The top 25 Gene Ontology pathways (biological processes) that were significantly enriched (P,0.01 after permutation) among the transcripts up-regulated after sleep
restriction. Total genes represents the number of genes that are annotated to the pathway. Top genes represents the number of genes that were found in the study
setting and contributed to the significance of the pathway.
doi:10.1371/journal.pone.0077184.t003
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combining 1 and 2 to a phenotype of ‘self-reported sufficient sleep’
and comparing this to 3, ‘self-reported insufficient sleep’. All
individuals with genome-wide Illumina RNA expression and sleep
insufficiency data (N= 472 individuals from DILGOM) were
included in the RNA expression correlation analysis.
The expression of three of the ten most up-regulated genes from
the experimental sleep restriction showed a trend for correlation
with self-reported insufficient sleep among the DILGOM subjects:
TLR4 (P=0.026, b= +0.27, Pcorrected = 0.26), HIPK3 (P=0.006,
b= +0.90, Pcorrected = 0.059), and FCRL2 (P=0.018, b=+1.02,
Pcorrected = 0.18), but it was not statistically significant after
correction with the number of genes analyzed in the population
sample (N= 10).
The expression of STX16 was significantly lower among
the subjects with insufficient sleep (P=0.0002, b=21.31,
Pcorrected = 0.002), while in the experimental sleep restriction study
it was among the 10 most up-regulated genes.
Three of the ten most down-regulated genes from the
experimental sleep restriction group correlated with self-reported
insufficient sleep in the DILGOM sample. The expressions of
TBX21 (P=1.8*107, b=20.78, Pcorrected = 1.8*10
6) and LGR6
(P=0.0007, b=20.79, Pcorrected = 0.007) were significantly lower
among the subjects reporting insufficient sleep, while TGFBR3
expression was higher in the group with insufficient sleep
(P=0.0001, b=+0.41, Pcorrected = 0.001). Also KIR3DL1
(P=0.028, b= +0.26, Pcorrected = 0.28) and GZMB (P=0.009,
b= +0.17, Pcorrected = 0.092) showed a trend for higher expression
with insufficient sleep, but these findings were not statistically
significant after correction for multiple testing.
C-reactive protein levels in the population sample
To examine whether the activation of the acute phase response,
seen in the experimental study as elevated CRP (19), was also
present in the population sample, we studied altogether 6803
individuals from the FINRISK 2007 that had answered the
question about sleep sufficiency (above) and had laboratory
measurements of serum CRP levels.
There was a significant association with CRP levels and self-
reported insufficient sleep among males. Males reporting insuffi-
cient sleep showed moderately, but statistically significantly, higher
CRP levels (mean 6 SD 2.6167.02 mg/l), than those who
reported that they were well rested (1.9264.13 mg/l) (P=0.0017).
No significant difference was found in females.
Discussion
The main finding of the study was that experimental sleep
restriction for one working week extensively activates the immune
system, up-regulating many immune response-related gene path-
ways and individual gene transcripts. Importantly, some of the
same genes that increased/decreased their expression in experi-
mental SR were affected also at population level in individuals
who reported insufficient sleep.
Lymphocyte activation
B cells. In the pathway analysis, the enrichment of genes
involved in B lymphocyte activation (pathway ‘‘B cell activation’’)
was most significant, indicating the activation of the humoral
immune system. Supporting this, we found also the pathway of
‘‘adaptive immune response based on somatic recombination of
immune receptors built from immunoglobulin superfamily do-
mains’’ among the top ranked pathways. Of the individual up-
regulated transcripts, SWAP70 is specifically expressed in B cells,
promoting B cell activation through immunoglobulin (Ig) G
binding as well as migration and adhesion of B cells [27].These
findings are in line with our previous observation showing that the
amount of B cells was increased in cumulative SR [19] and other
reports showing that parameters of humoral immunity, including
serum immunoglobulins (IgG, IgA, IgM), were elevated in sleep
deprivation [28]. The current results suggest that these sleep
restriction-induced changes in humoral immunity are regulated
also at the level of gene expression (Figure 3).
T cells. We observed the activation of T cells at transcrip-
tional level after SR. We found signs of activation of the T helper
cell 2 (Th2) type immune response pathways, which activate B
cell-mediated immunity. Accordingly, transcription factors SOCS3
and IKZF1, which drive Th2-development, were among the most
up-regulated transcripts after SR. However, the number of T-cells
was not changed (19).
T helper cell 1 (Th1) and Th2 lineages are reciprocally
inhibited. Accordingly, we found down-regulation of the T-box
transcription factor TBX21 (T-bet), the key regulator of the Th1-
differentation. TBX21 induces the production of the Th1-driving
cytokine IFN-c [29]. When we stimulated the leukocytes with T
cell-stimulating PHA and measured cytokine production, the
production of IFN-c was lower in the samples taken after SR
suggesting that SR may have a direct functional significance on
IFN-c via TBX21-mediated gene expression. Importantly, the
expression of TBX21 was down-regulated also in individuals who
reported insufficient sleep, implying down-regulation of the Th1
type immunity also at the population level (for more detailed
discussion, see below).
These findings suggest that cumulative SR may drive the
immune response towards Th2 cell type and further to B cell
activation and humoral immune response by inhibiting the Th1
activation line and by favoring the Th2 activation line (Figure 3).
Innate immunity-related findings
NK cells. NK cells form a part of the innate immune system
and are capable of recognizing infected or damaged cells. We and
others have previously reported a decrease in the number of NK
cells after SR [19,31]. In the present study, the pathway ‘‘MHC
class I receptor activity’’ was down-regulated after SR. This was
the only immune function related pathway that was down-
regulated. The MHC-I complex interacts with cytotoxic T cells
and NK cells, presenting mainly short peptides that originate
within the cell. The pathway consists mostly of genes coding for
killer cell immunoglobulin-like receptors. When the MHC-I
expression is down-regulated on target cells, the NK cells may
activate and destroy them (reviewed in [32]). The process is
mediated by secretion of cytotoxic proteases, such as granzymes,
which activate the caspase cascade in the target cells, eventually
leading to apoptosis [33]. We observed a down-regulation of genes
coding for granzymes B, H, and M (GZMB, GZMH, GZMM) after
SR, which may indicate decreased NK cell function. This may be
a way of protecting the cells from apoptosis, and/or contribute to
the weaker response in pathogen recognition and attenuated
immunity towards infections seen in SR [34] (Figure 3). As the
genes contributing significantly to the MHC-I pathway are
expressed in the NK cells we cannot rule out the possibility that
the reduced number of NK cells explains the down-regulation of
this pathway.
More than half of the 25 most down-regulated pathways were
related to cholesterol/lipid metabolism and transport. In addition,
several kinase pathways and a circadian rhythm pathway were
down-regulated. The changes induced by partial sleep restriction
in these functions remain a topic for further investigation.
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IL-8, TLR4, NF-kB, and STAT1. The second most signif-
icantly enriched pathway among the up-regulated genes was
‘‘interleukin 8 production’’. IL-8 acts as a mediator of acute
inflammatory response by recruiting monocytes and neutrophils
(reviewed in [35]). The major sources of IL-8 are monocytes and
macrophages, challenged by bacteria, viruses, or pro-inflammato-
ry cytokines (reviewed in [36]). Co-operative activation of
transcription factors NF-kB and AP-1 precede the IL-8 gene
transcription [36].The IL-8 production pathway up-regulation
comprised mainly of members of the family toll-like receptors
(TLRs 4, 7, and 8). TLRs recognize conserved pathogen patterns,
such as lipopolysaccharide (LPS), but also endogenous ligands.
Activation of these TLRs leads to the activation of the NF-kB
signaling cascade [37] leading to induction of several pro-
inflammatory cytokines, such as TNF-a and type I interferons
[38]. NF-kB activation has been observed in many pathological
states such as obesity and atherosclerosis [39] but also in SR
[21,22]. In the present study, TLR4 mRNA expression was
increased after SR, implying the activation of the early defense of
innate immunity pathway(s). Also several other TLRs showed a
trend for up-regulation after SR (Table S6). Accordingly, at the
population level, the expression of TLR4 showed a trend for a
positive association with insufficient sleep.
At pathway level, NF-kB signaling was up-regulated after
experimental SR. Binding sites for the transcription factors
STAT1 and IRF2 were concentrated among the up-regulated
transcripts after SR. One possible mechanism leading to NF- kB
activation is trough IRF2 mediated signaling, as the binding
sequences for IRF2 were enriched among the promoter regions of
the up-regulated genes. IRF2 regulates NF-kB activity by
Figure 3. Differentiation and activation of lymphocyte and other leukocyte populations in cumulative sleep restriction (SR). Arrows
(q) illustrate activating and blunt ended lines (T) inhibiting effects. Red = increased after SR, green = decreased after SR, grey = no change
observed. IFNc = interferon c, IL = interleukin, STAT1, TBX21 and SOCS3 = transcription factors, Ig = immunoglobulins. (The factors involved in T
helper (Th) cell differentiation modified after [30]). We propose that cumulative SR via the activation of B cell-mediated humoral immunity by Th2
cells may lead to increased risk for development or exacerbation of asthmatic symptoms. We also suggest that SR may participate in the
development of atherosclerosis through increased cholesterol intake into macrophages. On the other hand, the reduction in the NK cell type immune
response may be a mode to protect the self from destruction by apoptosis and/or might contribute to the attenuated immune response towards
pathogens.
doi:10.1371/journal.pone.0077184.g003
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modulating its cellular location [40]. Similarly, STAT1 has been
suggested to act as a point of convergence for the cross-talk
between the pro-atherogenic TLR4, IFN-c, and IL-6 activated
pathways in immune as well as vascular cells, amplifying pro-
inflammatory signals, increasing endothelial cell adhesion, and
possibly promoting the development of atherosclerosis [41]. Thus,
the present study offers further evidence of the activation of the
NF-kB pathway during sleep restriction through IRF2 and TLR4
mediated signaling. These changes may be relevant also at
population level.
Another function of STAT1, also possibly contributing to the
development or exacerbation of atherosclerosis, occurs in the
macrophages. STAT1 has been shown to increase the intake of
cholesterol into macrophages [42]. Cholesterol uptake depletes
calcium stores in the endoplasmic reticulum (ER) and activates
the unfolded protein response (UPR) [43,44]. ER stress and UPR
have been shown earlier to be induced also by sleep restriction in
the brain of model organisms [45,46]. Burden from ER stress
together with TLR4 and STAT1 activation has been suggested
as the mechanism leading to macrophage apoptosis [47] which,
especially in late atherosclerotic lesions, can be detrimental
(reviewed in [48]).
Also IRF2 has been reported to participate in the regulation of
macrophage apoptosis through a STAT1/3-dependent mecha-
nism [49]. These mechanisms may possibly contribute to the
increased development of atherosclerosis in SR (Figure 3).
CRP. We and others have previously reported that experi-
mental SR increases serum CRP levels [19,20]. The pathway
analysis of the present study showed activation of the IL-8
biosynthesis pathways. IL-8 has been shown to mediate the
production of CRP and other acute phase proteins [50]. It has
been suggested to act with IL-6 as the main acute phase response
mediator in patients with myocardial infarction [51]. Chronic, low
level increase in CRP has been associated with cardiovascular
diseases [52], short sleep duration [53,54] and sleep restriction
[19,20]. Accordingly, we found elevated CRP levels in men that
reported insufficient sleep in the population sample. Associations
between higher CRP have earlier been reported in women [53,55]
and adolescents [54] with short sleep duration, and in men with
sleep disturbances [56].
We propose that SR may convey its pro-atherogenic responses
through an NF-kB- and TLR4-mediated inflammation reaction,
IL-8- and CRP-mediated acute phase response, IL-8-mediated
leukocyte adhesion to endothelium, and STAT1-mediated chang-
es in macrophages. On the other hand, Th2-type immune
response and activation of B cells may contribute to the
development or exacerbation of certain inflammatory disease
states, such as asthmatic symptoms (Figure 3).
In summary, these results indicate that components of both
innate immunity and adaptive immune systems become activated
in SR, which may be relevant for general health also at the
population level.
Population study findings
Most studies on physiological changes in sleep restriction have
been conducted using continuous waking for 1–3 days. The few
comparisons between the continuous waking condition and
partial sleep restriction for 4–5 days show that some brain
functions in humans [57], as well as the immune system in rats
[58] react differently to these challenges. Recently, Mo¨ller-Evert
et al. studied the interaction of circadian phase with moderate
cumulative sleep deprivation and acute total sleep loss, and the
effects of these on blood transcriptome [59]. They reported that
moderate sleep restriction (6 h sleep/night) for one week
modified the circadian oscillation of gene expression and the
response to acute sleep loss.
Even more differences can be expected if the restriction lasts for
months and years, as may be the case with the individuals who
report insufficient sleep in the population study. During prolonged
exposure to sleep restriction, the original changes may become
compensated, and even introduce new harmful factors that
threaten health. In spite of possible confounding factors, we were
able to identify several genes whose expression levels associated to
both experimental sleep restriction and subjectively experienced
insufficient sleep. Statistically significant associations, corrected for
multiple testing, were observed for the transcripts TBX21 and
TGFBR3, which are mediators of the immune system, and LGR6
and STX16 that have been repeatedly associated with cancer
progression. Our findings highlight the potential role of these
individual transcripts in response to SR, both in experimental and
in population level.
In addition, suggestive evidence for association at the popula-
tion level was found for several genes whose expression was
changed after experimental SR. The two genes on the top of the
list of the up-regulated individual genes in experimental SR were
TLR4 and HIPK3. A trend for increase for both genes was
observed also in the population study among subjects that reported
insufficient sleep. As discussed above, TLR4 and NF-kB are key
regulators of the innate immune system. Interestingly, TLR4
knock-out mice express an attenuated response for sleep depriva-
tion [60]. A recent publication reports that TLR4 mRNA is
increased in patients with metabolic syndrome [61], which also is a
risk factor for cardiometabolic diseases.
Results from the population-based sample show that the
expression of some of the genes that changed their expression
during experimental sleep restriction correlated with subjectively
experienced insufficient sleep. This finding expands the timespan
of sleep restriction beyond the experimental restriction and shows
that restricted/insufficient sleep affects the same physiological
processes also in natural living conditions. Importantly, these
findings suggest that detrimental effects of insufficient sleep may be
carried out at the population level by the same molecules that were
identified in the experimental SR.
Previous epidemiologic studies, based on questions about sleep
duration or insomnia and findings such as an increase in CRP,
have suggested a causative relationship between cardiometabolic
diseases and insufficient sleep (reviewed in [62]). The increases in
CRP levels were identified also in our study, and together with the
transcriptional evidence of activation of the immune system give
further support to the connection between insufficient sleep and
cardiometabolic diseases at population level.
The question of the present epidemiologic study targeted
directly the sufficiency/insufficiency of sleep. We believe this
question may be more relevant since it avoids the problem of
natural short sleepers, who form a confounding factor when using
short sleep duration as a marker of insufficient sleep. This issue
was discussed in a recent paper by Altman et al. [63], prompted by
results showing that some cardiovascular outcomes associated
differently to sleep duration and sleep insufficiency.
It can be noted that the cohort that was used in the genome-
wide expression analysis is small for an epidemiological cohort,
and thus the results need to be confirmed in a larger cohort.
Taken together, these findings introduce possible mechanisms
through which sleep restriction could, by activating immune
responses, predispose to conditions where activation of the
immune system plays a role in the pathogenesis of the condition.
Such diseases include cardiovascular diseases and type II diabetes,
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whose development is initiated with prolonged, low level
inflammation [23].
Conclusions
This is the first study to address gene expression changes
induced by cumulative sleep restriction in humans at whole
genome level in experimental conditions and a population sample.
Sleep restriction appears to induce a threat for the body, which
leads to extensive activation of both the innate and the acquired
immune system. A prolonged condition of insufficient sleep
maintains this activation, at least partly, leading to chronic, low-
level inflammation – a well-known contributor to many detrimen-
tal health conditions, including cardiometabolic diseases.
Materials and Methods
Experimental SR study participants and design
The SR experiment has been reported by [19]. In short,
fourteen healthy men, aged 19–29 (mean 6 SD age
23.162.5 years), with a regular sleep-wake schedule and habitual
sleep duration of 7–9 h participated in the study. During the
experiment, the experimental group (N= 9) spent 8 h in bed for
the first two nights (baseline (BL), from 11 PM to 7 AM), followed
by 5 nights where they spent only 4 h in bed (sleep restriction (SR),
from 3 AM to 7 AM) and, finally, again 2 nights of 8 h in bed
(recovery (REC), from 11 PM to 7 AM). The control group (N= 5)
spent 8 h in bed (11 PM to 7 AM) throughout the entire
experiment. Continuous EEG recordings and a continuously
present investigator served to monitor that the participants did not
sleep during the periods outside those mentioned above. One
control subject deviating from normal sleep pattern was excluded
in the quality control phase. Total sleep duration decreased in the
experimental group during SR accordingly (mean 6 SD sleep/
night BL 439620 min, SR 23265 min) [19]. There was only a
modest (16 min) delay in the circadian rhythm measured by the
morning peak timing of saliva cortisol [15], and no overall changes
in cortisol levels were observed [19].
Meals were standardized and energy-balanced based on the
current national recommendations, provided at fixed times and
consumed by all participants throughout the experiment. During
waking, the participants could not leave the building but took part
in activities simulating a working week (including psychomotor
vigilance task, memory and motor tasks etc.). The study design was
approved by the ethics committee of the Hospital District of
Helsinki and Uusimaa, and a written informed consent was
obtained from the participants. The experiment was conducted at
the Brain and Work Research Centre of the Finnish Institute of
Occupational Health.
Peripheral blood mononuclear cells, RNA isolation, and
expression microarrays
Heparinized venous blood samples were collected in sitting
position from 9 participants from the experimental group and 4
participants from the control group similarly at 7:30 AM before
breakfast after BL, SR, and REC. Peripheral blood mononuclear
cells (PBMC) were isolated using Ficoll density gradient centrifu-
gation.
Total RNA was extracted by using Trizol (Gibco BRL, Paisley,
UK). Final RNA concentrations were determined spectrophoto-
metrically, and RNA quality was assessed using Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). RNA
expression levels were assayed with Affymetrix GeneChip Human
Genome U133 Plus 2.0 arrays (Affymetrix Inc., Santa Clara, CA,
USA).
Microarray quality control
Quality control of the expression arrays was performed with
GeneSpring GX software (Agilent Technologies, Palo Alto, CA,
USA). GCRMA algorithm was used for normalizing the data
[64].
Following this, the Affymetrix detection calls [65] were used as a
filtering criterion and probes flagged ‘present’ or ‘marginal’ in less
than 2/3 of the samples were filtered out. This phase decreased
the number of probes from the original 54613 to 21026.
The probes on all chips were remapped to updated Ensemble
database probe set definitions (version homo_sapiens_core_
54_36). After removing the un-annotated probes, 15101 probes
remained (Figure 1a), each corresponding to a specific transcript
(some genes having more than one probe).
Transcription factor binding site analysis
Enrichment of binding sites for specific transcription factors
among the up- or down-regulated genes was analyzed using the
over-representation analysis tool oPOSSUM [24]. Human single
site analysis was applied encompassing 5000 base pairs both
upstream and downstream from the transcription start site of each
gene. One-tailed Fisher exact probability test P values below 0.05
were considered significant.
Pathway analysis
In order to characterize which biological pathways were
enriched, a nonparametric in house developed CIGA pathway
analysis program was used. This program uses Gene Ontology
(GO) annotations that group the single genes in biologically
meaningful pathways [25].
The analysis in the first phase consisted of all transcripts that
survived probe filtering (see Figure 1a) comprising altogether
15101 transcripts. In order to study pathways which were
activated or inactivated, the probes were divided into up- and
down-regulated probes and sorted by the repeated measures
ANOVA P value. The pathway analysis program calculates the P
value by answering the question: ‘‘how likely is it to see this many
genes (k) that belong to the studied pathway this high-up in the
ranked list of genes (j), when there are altogether t genes that
belong to the pathway amongst n genes in the experiment’’.
p(j,k,t,n)~1{
Xk{1
c~0
j
c
 
n{j
t{c
 
n
t
 
The P values were calculated as pointwise P values and
permutated 1 000 times to obtain corrected P values. Pathways
with total number of 3 genes or less were excluded from the
results.
Quantitative PCR validation of gene expression
Specific primers were ordered from Oligomer (Helsinki,
Finland). Detailed primer sequences are available on request.
The cDNA was synthesized with the DyNAmoTM cDNA
Synthesis Kit F-470L for qRT-PCR (Finnzymes, Helsinki, Fin-
land) according to manufacturer’s instructions. The qPCR
reactions were performed as quadruplicates with DyNAmoTM
Flash SYBRH Green qPCR Kit (Finnzymes) using AbiPrism
7900HT detection system (Applied Biosystems, Foster City, CA,
USA). The data were analyzed using SDS software for AbiPrism
7900HT.
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The relative fold difference in gene expression between SR and
BL was calculated by the DDCt method with qBasePLUS software
(Biogazelle NV, Ghent, Belgium) taking gene specific amplification
efficiencies into account [66]. The expression stability of the
internal control (‘‘housekeeping’’) genes PPIA and RPLP0 was
evaluated using geNormPLUS algorithm (Biogazelle) [67]. The
statistical significance of the changes was assessed by paired t tests,
and P values under 0.05 were considered significant.
Interferon c production in proliferated PBMC
Proliferation of PBMC was performed with PHA (45 mg/mL;
Murex Biotech Ltd, Dartford, UK) as described in [19]. IFN-c
protein analysis was made with the Luminex bead system (Bio-Plex
200 System, Bio-Rad Laboratories, Hercules, CA, USA) by
labelled cytokine capture antibody pairs (Bio-Rad Laboratories) as
reported in [19]. IFN-c protein levels in cells stimulated after SR
were compared with a paired t test to those of cells taken from BL
and stimulated similarly.
RNA expression and CRP in the population cohort
For RNA expression analysis, the biotinylated cRNA were
hybridized onto Illumina HumanHT-12 Expression BeadChips
(Illumina Inc., San Diego, CA, USA) using standard protocol. For
each sample, biotinylated cRNA preparation and hybridization
onto BeadChip were done in duplicates [68]. Quality control and
data processing were done as stated in [68]. In short, probe
intensity distributions for all arrays were set to the same level by
quantile normalization. Technical replicates with Pearson corre-
lation coefficient P$0.94 or Spearman’s rank correlation coeffi-
cient r$0.60 were accepted (9 samples were excluded). Linear
regression model was used to correlate RNA expression with self-
reported insufficient sleep adjusting for age and gender with R
version 2.13.
CRP was measured from plasma using a latex immunoassay
(Sentinel Diagnostics, Milan, Italy) with Architect c8000 clinical
chemistry analyzer (Abbott Laboratories, Abbott Park, Illinois,
US). General linear model was used for correlating CRP levels
with self-reported insufficient sleep with PASW Statistics version
18 (IBM). Genders were analyzed separately (N males = 1529; N
females = 1892) adjusting for age (but not for comorbidities).
Data availability
The expression data has been made puclicly available through
the ArrayExpress database (accession numbers E-MEXP-3936
and E-TABM-1036 for the experimental and population data sets,
respectively).
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